Chipscreen
chipscreen.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
中国原创新药领域拓荒者 集团概况 管理团队 微芯历史 集团荣誉 社会责任 首页 关于微芯 集团概况 微芯生物是一家以核心技术驱动，构建具有全球竞争力产品线的原创新药企业。作为中国原创新药领域的拓荒者，公司秉持“原创、安全、优效、中国”的理念，致力于为患者提供临床亟需的、具有革命性疗效的创新机制药物。公司已形成从早期探索性发现到商业化的完整产业链布局，为全球患者提供中国原创新药。 基于中国早期研究的全球开发策略，微芯生物汇聚相关领域具有资深经验的顶尖科学家团队，应用AI+化学基因组学整合式技术平台，打通了从基础研究到临床转化的全过程，已成功开发出抗肿瘤药物爱谱沙®…
News
Chipscreen Biosciences
Shenzhen Chipscreen Biosciences Co., Ltd. ("Chipscreen Biosciences") announced that its wholly owned subsidiary, Chipscreen Biosciences (USA) Ltd., has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for i
Read more
Report
Shenzhen Chipscreen Biosciences Co., Ltd.
The Nature Index tracks the affiliations of scientific articles from high-quality publications. The research profile for Shenzhen Chipscreen Biosciences Co., Ltd. reflects the research output of authors from Shenzhen Chipscreen Biosciences Co., Ltd. who p
Read more
Report
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
Read more
Report
Biocytogen's Subsidiary Eucure Biopharma and Chipscreen Biosciences' Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for ...
Read more
Report
Chipscreen Biosciences Announces NMPA New Drug Approval of Bilessglu (Chiglitazar Sodium tablets) for ( Type 2 Diabetes) in China
Read more
Report
Chipscreen and Novogene enter a strategic partnership for companion diagnostics development
SHENZHEN, China, Oct. 8, 2019 /PRNewswire/ -- Chipscreen Biosciences Co., Ltd. (Chipscreen, Stock Symbol: 688321.SH) and Novogene Co., Ltd. (Novogene) recently announced a strategic partnership for companion diagnostics (CDx) development. Under the agreem
Read more
Report
Chinese drugmaker Chipscreen
SHANGHAI/HONG KONG (Reuters) - Shenzhen Chipscreen Biosciences, which plans to list on China
Read more
Report